The aim of this study was to investigate the potential for dexfenfluramine (dF) to improve cardiovascular risk factors and compliance toward the diet in a group of prepubertal individuals, hospitalized for essential obesity of high degree (BMI ≥ 30). 22 subjects (mean age 12.6 ± 0.4 years) participated in a 9-week randomized double-blind study of dF (15 mg twice a day) (group A) versus placebo (group B); during the study all patients received a standard diet (1000 KCal/day). In basal conditions and after 30 and 60 days of therapy, anthropometric variables (height, weight and BMI) and cardiovascular risk factors (glycemia, total cholesterol, HDL-C, triglycerides, systolic and diastolic blood pressure) were monitored. Modifications of hunger and satiety were also assessed. All the patients underwent 30 day controls, while 7 members of group A and 4 of group B finished the study. During the treatment period dF group and placebo group lost weight similarly (BMI = dF: 34.1 ± 1.9 vs 30.7 ± 1.6 vs 28.5 ± 1.5; placebo: 30.8 ± 0.8 vs 28.6 ± 0.8 vs 27.2 ± 0.2); in neither group the therapy induced important side effects. In both groups systolic blood pressure, total cholesterol and HDL-C decreased significantly; a greater reduction of HDL-C in subjects treated with placebo after 60 days was the only significant difference observed with respect to those with dF (25 ± 1 vs 30 ± 1 mg/dl: p <0.01). As concerns others data, in both groups a reduction in hunger and an increase in satiety were obtained, without differences between subjects treated with dF and placebo. These findings demonstrate that the use of dF in the treatment of essential obesity in prepubertal subjects does not bring any substantial advantages compared to dieting, at least not when total caloric consumption is strictly supervised.
|Number of pages||10|
|Journal||Acta Medica Auxologica|
|Publication status||Published - 1995|
- prepubertal age
ASJC Scopus subject areas